Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Medtronic updates AneuRx system

This article was originally published in The Gray Sheet

Executive Summary

A newer version of Medtronic's AneuRx AAAdvantage abdominal aortic aneurysm (AAA) stent graft with the Xcelerant delivery system wins FDA approval. Updates to the new system include improved radiopaque markers and stent contouring. Roughly 1.2 mil. people in the United States have AAA, though only 15% are ever diagnosed, according to Medtronic. The AneuRx system was originally launched in the U.S. in 1996 (1"The Gray Sheet" Nov. 28, 2005, p. 9)...

You may also be interested in...

Endovascular AAA Repair Requires Reintervention More Often Than Surgery

Reintervention to address abdominal aortic aneurysm (AAA) repair complications is more common following endovascular procedures than with open surgery, according to Vascular Surgery Chief Jan Blankensteijn, MD, Radboud University Nijmegen Medical Center, The Netherlands

AstraZeneca's Risky Lynparza Endpoint In Pancreatic Cancer Goes Before Advisory Cmte.

US FDA usually recommends using overall survival for pancreatic cancer drugs, but AstraZeneca choose progression-free survival; now ODAC will weigh in on whether the PARP inhibitor olaparib demonstrated a clinically meaningful impact. The firm cites enrollment and design challenges in the gBRCAm population as reasons for using PFS.

Did Sarepta Need To Tell Investors About Its Vyondys 53 Dispute Resolution Request?

Attorneys say Sarepta did not have an obligation to report its appeal, particularly since winning a formal dispute filing with the US FDA is a long shot.




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts